| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $2,771,829 | 7 | 100 |
Sells | $0 | 0 | 0 |
| Hoffman Michael B | director | 6 | $2.57M | 0 | $0 | $2.57M |
| Maccecchini Maria-Luisa | President & CEO | 1 | $200,000 | 0 | $0 | $200,000 |
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Over the last 12 months, insiders at Annovis Bio, Inc. have bought $2.77M and sold $0 worth of Annovis Bio, Inc. stock.
On average, over the past 5 years, insiders at Annovis Bio, Inc. have bought $1.71M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Hoffman Michael B (director) — $2.57M. Maccecchini Maria-Luisa (President & CEO) — $200,000.
The last purchase of 45,000 shares for transaction amount of $193,794 was made by Hoffman Michael B (director) on 2025‑12‑08.
| 2025-12-08 | Hoffman Michael B | director | 45,000 0.2279% | $4.31 | $193,794 | -15.12% | ||
| 2025-11-24 | Hoffman Michael B | director | 39,200 0.2144% | $4.08 | $159,886 | -8.56% | ||
| 2025-11-24 | Hoffman Michael B | director | 28,096 0.1564% | $4.15 | $116,598 | -8.56% | ||
| 2025-11-21 | Hoffman Michael B | director | 20,000 0.0937% | $3.50 | $69,900 | -0.26% | ||
| 2025-11-14 | Hoffman Michael B | director | 15,000 0.0703% | $2.11 | $31,650 | +59.83% | ||
| 2025-10-28 | Hoffman Michael B | director | 975,610 5.0805% | $2.05 | $2M | +71.43% | ||
| 2025-10-28 | Maccecchini Maria-Luisa | President & CEO | 97,561 0.508% | $2.05 | $200,000 | +71.43% | ||
| 2021-10-12 | White Mark K. | director | 5,000 0.148% | $27.40 | $137,000 | -49.71% | ||
| 2021-10-11 | Maccecchini Maria-Luisa | PRESIDENT AND CEO | 18,000 0.5368% | $27.61 | $496,980 | -49.37% | ||
| 2021-10-11 | Bruck Claudine | director | 181 0.0054% | $27.66 | $5,006 | -49.37% | ||
| 2021-08-19 | McCarthy Reid | director | 500 0.0203% | $37.61 | $18,805 | -59.74% | ||
| 2020-02-03 | McGroarty Jeffrey Brian | Chief Financial Officer | 19,500 0.1506% | $7.15 | $139,428 | -30.90% | ||
| 2020-01-31 | Maccecchini Maria-Luisa | President and CEO | 1,600 0.0104% | $6.00 | $9,600 | -23.31% | ||
| 2020-01-31 | Hoffman Michael B | 33,333 0.216% | $6.00 | $199,998 | -23.31% | |||
| 2020-01-31 | McGroarty Jeffrey Brian | Chief Financial Officer | 33,333 0.216% | $6.00 | $199,998 | -23.31% | ||
| 2020-01-31 | Whelan, Jr. Robert M. | director | 25,000 0.162% | $6.00 | $150,000 | -23.31% | ||
| 2020-01-31 | White Mark K. | director | 1,734 0.0112% | $6.00 | $10,404 | -23.31% | ||
| 2020-01-31 | Bruck Claudine | director | 800 0.0052% | $6.00 | $4,800 | -23.31% |
| Hoffman Michael B | director | 2574739 13.0873% | $7.78M | 7 | 0 | |
| Maccecchini Maria-Luisa | President & CEO | 1212020 6.1606% | $3.66M | 3 | 0 | <0.0001% |
| White Mark K. | director | 56177 0.2855% | $169,654.54 | 2 | 0 | <0.0001% |
| McGroarty Jeffrey Brian | Chief Financial Officer | 52833 0.2685% | $159,555.66 | 2 | 0 | |
| Whelan, Jr. Robert M. | director | 25000 0.1271% | $75,500.00 | 1 | 0 | |
| McCarthy Reid | director | 6829 0.0347% | $20,623.58 | 1 | 0 | <0.0001% |
| Bruck Claudine | director | 6067 0.0308% | $18,322.34 | 2 | 0 | <0.0001% |
$1,695,621 | 55 | 17.90% | $56.63M | |
$103,288,323 | 51 | 4.78% | $70.42M | |
$693,326 | 47 | -16.18% | $67.57M | |
$24,478,755 | 37 | -34.59% | $49.41M | |
$36,180,184 | 32 | 41.36% | $67.83M | |
$27,151,286 | 27 | -16.85% | $64.69M | |
$555,628 | 21 | 43.52% | $59.29M | |
$26,736,140 | 20 | -18.64% | $51.98M | |
$6,733,543 | 17 | -19.02% | $75.79M | |
$20,234,041 | 17 | 2.09% | $56.26M | |
$17,594,514 | 16 | -20.37% | $58.63M | |
$277,862 | 15 | 59.79% | $73.37M | |
$3,763,566 | 15 | -21.70% | $55.67M | |
$106,599,960 | 6 | -7.63% | $62.26M | |
$26,254,149 | 5 | 49.97% | $49.97M | |
Annovis Bio, Inc. (ANVS) | $657,791 | 4 | -52.05% | $59.41M |
$67,369,250 | 3 | -22.09% | $64.69M | |
$12,498 | 2 | 39.61% | $67.07M | |
$4,030 | 1 | 9.14% | $58.44M |
| Increased Positions | 16 | +36.36% | 404,665 | +22.38% |
| Decreased Positions | 12 | -27.27% | 157,826 | -8.73% |
| New Positions | 5 | New | 67,586 | New |
| Sold Out Positions | 5 | Sold Out | 116,814 | Sold Out |
| Total Postitions | 48 | +9.09% | 2M | +13.65% |
| Vanguard Group Inc | $2,694.00 | 2.73% | 738,003 | +41,239 | +5.92% | 2025-09-30 |
| Susquehanna International Group, Llp | $797.00 | 0.81% | 218,421 | +53,863 | +32.73% | 2025-09-30 |
| Geode Capital Management, Llc | $672.00 | 0.68% | 184,154 | +867 | +0.47% | 2025-09-30 |
| Citadel Advisors Llc | $636.00 | 0.65% | 174,345 | +145,019 | +494.51% | 2025-09-30 |
| Northern Trust Corp | $442.00 | 0.45% | 121,060 | +61,546 | +103.41% | 2025-09-30 |
| Merit Financial Group, Llc | $297.00 | 0.3% | 81,316 | -10,000 | -10.95% | 2025-09-30 |
| Blackrock, Inc. | $294.00 | 0.3% | 80,675 | 0 | 0% | 2025-09-30 |
| Greenwich Wealth Management Llc | $173.00 | 0.18% | 47,400 | +400 | +0.85% | 2025-09-30 |
| Wescott Financial Advisory Group, Llc | $152.00 | 0.15% | 41,607 | 0 | 0% | 2025-09-30 |
| State Street Corp | $140.00 | 0.14% | 38,435 | 0 | 0% | 2025-09-30 |